Aweeka, Francesca, Pharm.D.

Professor, School of Pharmacy, Dept of Clinical Pharmacy, UCSF and Director, Drug Research Unit,


E-mail Address:  faweeka@sfghsom.ucsf.edu

 

Aweeka, Francesca

Current Main Activities:
Pharmacokinetics and pharmacodynamics: primarily in anti-viral and antimalarial drugs

 

Education and Training:
Pharmacokinetics/Pharmacodynamics Research Fellow, 1986-88

Resident in Clinical Pharmacy, University of California, San Francisco, 1985-86

Pharm.D., University of California, San Francisco, 1985

Bachelor of Science, University of Southern California, 1981

 

Publications:

1. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29;367(22):2110-8. PMID: 23190222.


2. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):310-6. PMID: 22918158.


3. Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, Van Heeswijk R, Flexner C; the ACTG 5267 Study Team. Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) with Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Im Defic Syndr. 2012 Apr 15;59(5):455-462. PMID: 22126739


4. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29;367(22):2110-8. PMID: 23190222.


5. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):310-6. PMID: 22918158.


6. Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, Van Heeswijk R, Flexner C; the ACTG 5267 Study Team. Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) with Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Im Defic Syndr. 2012 Apr 15;59(5):455-462. PMID: 22126739


7. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012 Nov;42(11):1088-95. PMID: 22671777.


8. Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Res Treat. 2012;2012:703604. PMID: 22500218


9. Huang L, Li X, Marzan F, Lizak PS, Aweeka FT. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012 Jan;4(2):157-66. PubMed PMID: 22250798.


10. Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, Sawe F, Currier JS, Lockman S, Aweeka FT; for the AIDS Clinical Trials Group Study 5208 Team. Nevirapine (NVP) pharmacokinetics (PK) and risk of rash and hepatitis among HIV-infected Sub-Saharan Women. AIDS. 2012 Feb 1. PMID 22301417


11. Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark TD, Dorsey G, Lindegardh N, Annerberg A Rosenthal PJ, Kamya MR, Aweeka F Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.. Antimicrob Agents Chemother. 2010 Jan;54(1):52-9. PMID:19841149


12. Huang L, Lizak PS, Jayewardene AL, Marzan F, Lee MN, Aweeka FT. A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. Anal Chem Insights. 2010 Mar 29;5:15-23. PMID: 20448843


13. Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE. J Contraceptive efficacy of oral and transderman hormones when co-administered with protease inhibitors in HIV-1 infected women pharmacokinetic results of ACTG trial A5188. Acquir Immune Defic Syndr. 2010 Dec 1;55(4):473-82. PMID: 20842042


14. Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Medicine (HIV Med) 2010;11:232-8 PMID:20002783.


15. German P, Parikh S, Lawerence J, Lindegardh N, Rosenthal P, Havlir D, Charlegois E, Dorsey G, Aweeka FT. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV uninfected healthy volunteers. Acquir Immune Defic Syndr. 2009 Aug 1:51(4):424-9 PMID:19506482


16. Huang L, Jayewardene A, Xiaohua L, Marzan F, Lizak P, Aweeka F. Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma. J Pharm Biomed Anal. 2009 Dec 5;50(5):959-65. PMID:19646837


17. Capparelli EV, Aweeka FT, Hittii J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnik M; PACTG 1026S Study Team; PACTG P1022 Study Team. Chronic administration of nevirapine during pregnancy; impact of pregnancy on pharmacokinetics. HIV Med. 2008 Apr;9(4):214-20. PMID:18366444


18. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, Lindegardh N, Havlir D, Aweeka FT. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007 Mar 15;44(6):889-91.PMID:17304470